Abbvie (ABBV) Weakness Related to Hep-C Data from Gilead (GILD), BMO Capital Says

April 23, 2015 11:47 AM

BMO Capital analyst Alex Arfaei weighed in on Abbvie (NYSE: ABBV) following Q1 results. The analyst said Street Hep-C ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found